Trovagene Investor Relations http://trovagene.investorroom.com/ Trovagene Investor Relations Trovagene Presents Data at AACR Meeting 2018 on Pharmacodynamic and Tumor Biomarkers During Treatment with PCM-075 and Low-Dose Cytarabine http://trovagene.investorroom.com/2018-04-17-Trovagene-Presents-Data-at-AACR-Meeting-2018-on-Pharmacodynamic-and-Tumor-Biomarkers-During-Treatment-with-PCM-075-and-Low-Dose-Cytarabine Methodology to assess changes in leukemic cells, genomic alterations and pTCTP status for Phase 1b/2 Clinical Trial of PCM-075. Update on clinical trial recruitment. Tue, 17 Apr 2018 11:00:00 -0700 http://trovagene.investorroom.com/2018-04-17-Trovagene-Presents-Data-at-AACR-Meeting-2018-on-Pharmacodynamic-and-Tumor-Biomarkers-During-Treatment-with-PCM-075-and-Low-Dose-Cytarabine Trovagene Presents Data at AACR Meeting 2018 Showing Synergy of PCM-075 in Combination with FLT3 Inhibitors in Acute Myeloid Leukemia (AML) http://trovagene.investorroom.com/2018-04-16-Trovagene-Presents-Data-at-AACR-Meeting-2018-Showing-Synergy-of-PCM-075-in-Combination-with-FLT3-Inhibitors-in-Acute-Myeloid-Leukemia-AML Combination of PCM-075, a highly-selective Polo-like Kinase 1 (PLK1) inhibitor, and Quizartinib resulted in 97% tumor growth inhibition and regression in FLT3 AML model Mon, 16 Apr 2018 06:00:00 -0700 http://trovagene.investorroom.com/2018-04-16-Trovagene-Presents-Data-at-AACR-Meeting-2018-Showing-Synergy-of-PCM-075-in-Combination-with-FLT3-Inhibitors-in-Acute-Myeloid-Leukemia-AML Trovagene Announces Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2018 http://trovagene.investorroom.com/2018-04-12-Trovagene-Announces-Presentations-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2018 Thu, 12 Apr 2018 13:11:00 -0700 http://trovagene.investorroom.com/2018-04-12-Trovagene-Announces-Presentations-at-the-American-Association-for-Cancer-Research-AACR-Annual-Meeting-2018 Trovagene to Present at the 26th Annual Wall Street Investor Conference http://trovagene.investorroom.com/2018-03-20-Trovagene-to-Present-at-the-26th-Annual-Wall-Street-Investor-Conference Tue, 20 Mar 2018 05:00:00 -0700 http://trovagene.investorroom.com/2018-03-20-Trovagene-to-Present-at-the-26th-Annual-Wall-Street-Investor-Conference Trovagene Announces First Patient Successfully Completes Cycle 1 of Treatment with PCM-075 in Combination with Low Dose Cytarabine (LDAC) in AML Trial http://trovagene.investorroom.com/2018-03-05-Trovagene-Announces-First-Patient-Successfully-Completes-Cycle-1-of-Treatment-with-PCM-075-in-Combination-with-Low-Dose-Cytarabine-LDAC-in-AML-Trial Mon, 05 Mar 2018 05:00:00 -0800 http://trovagene.investorroom.com/2018-03-05-Trovagene-Announces-First-Patient-Successfully-Completes-Cycle-1-of-Treatment-with-PCM-075-in-Combination-with-Low-Dose-Cytarabine-LDAC-in-AML-Trial